Ensign Peak Advisors Inc Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ensign Peak Advisors Inc lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,464 shares of the biopharmaceutical company’s stock after selling 4,104 shares during the period. Ensign Peak Advisors Inc owned approximately 0.06% of Alnylam Pharmaceuticals worth $17,993,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Nordea Investment Management AB increased its stake in Alnylam Pharmaceuticals by 6.7% in the 4th quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company’s stock valued at $2,417,000 after buying an additional 637 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 0.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock valued at $1,532,000 after acquiring an additional 58 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company’s stock valued at $624,000 after acquiring an additional 63 shares in the last quarter. Pallas Capital Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.6% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company’s stock worth $802,000 after acquiring an additional 87 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after purchasing an additional 2,285 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Chardan Capital lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a report on Friday, May 2nd. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. UBS Group raised their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, Royal Bank of Canada upped their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $319.17.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $252.00 on Monday. The firm has a fifty day simple moving average of $250.53 and a 200-day simple moving average of $253.70. The company has a market capitalization of $32.86 billion, a PE ratio of -116.13 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the prior year, the firm posted ($0.16) earnings per share. Alnylam Pharmaceuticals’s revenue was up 20.2% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,561 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the transaction, the chief marketing officer now owns 13,537 shares of the company’s stock, valued at $3,454,236.29. This trade represents a 10.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This trade represents a 4.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock worth $1,875,627 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.